21 July 2023
21 July 2023
The NCRI announced it will be winding down after 22 years. What does this mean for global research? How will smaller charities manage to remain involved in research?
The Phase II trial for Zynlonta and Rituxan in DLBCL patients was discontinued after the FDA placed a partial clinical hold on the trial.
A non-statistically significant reduction of nearly 16% in influenza A protocol-defined illness was observed.
Metabolic disorders top the chart as the highest talked about therapy area this week on Tweeter with 101 posts.
BMB-101 demonstrated favourable safety and tolerability profile with transient, dose-dependent increases in prolactin.
Immune responses will be assessed at the interim and final analyses in each arm.
Evaluating the endocrine sensitive disease rate after four weeks of treatment is the primary objective of the study.
Teleflex is currently conducting two studies for its device in patients undergoing percutaneous coronary intervention.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
